Mangafodipir (trisodium)

Mangafodipir trisodium (MnDPDP), hepatocellular-specific contrast agent, is an efficacious inhibitor of CIPN (chemotherapy-induced peripheral neuropath) and other conditions caused by cellular oxidative stress. Mangafodipir trisodium shows no negative interference with the tumoricidal activity of chemotherapy[1][2].

Product Specifications

CAS Number

[140678-14-4]

Product Name Alternative

MnDPDP

UNSPSC

12352005

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Mangafodipir-trisodium.html

Purity

99.82

Solubility

H2O : 33.33 mg/mL (ultrasonic)

Smiles

O=C1[O-][Mn+2]([N]2(C3)CC4=C5COP(O)(O)=O)([O-]C6=C(N=C7)C)([O-]C4=C(N=C5)C)([O-]C3=O)[N](CC6=C7COP([O-])(O)=O)(CC2)C1.[Na+].[Na+].[Na+]

Molecular Formula

C22H27MnN4Na3O14P2

Molecular Weight

757.32

References & Citations

[1]Karlsson JOG, et al. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN) . Transl Oncol. 2017 Aug;10 (4) :641-649. |[2]Wang C. Mangafodipir trisodium (MnDPDP) -enhanced magnetic resonance imaging of the liver and pancreas. Acta Radiol Suppl. 1998;415:1-31.|[3]Qin Y, et al. Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice. Reprod Biol Endocrinol. 2018 Oct 27;16 (1) :106.